A Phase 2 interventional study of VRB-101 and Placebo in Obesity and Overweight, sponsored by Verdiva Bio Dev Limited. Completed at 22 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Verdiva Bio Dev Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
This is a randomized, double-blind, placebo-controlled study of oral ecnoglutide (VRB-101), with 5 active arms and 1 placebo arm. The study will include a Screening Period of 4 weeks, followed by a 20-week Study Treatment Period and a 4-week Safety Follow-up Period prior to the end of study (EOS) visit.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 206 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Verdiva Bio Dev Limited is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive VRB-101 once every week.
Drug: VRB-101
Participants will receive VRB-101 once every week.
Drug: VRB-101
Participants will receive VRB-101 once every week.
Drug: VRB-101
Participants will receive VRB-101 once every week.
Drug: VRB-101
Participants will receive VRB-101 once every week.
Drug: VRB-101
Participants will receive matching placebo to VRB-101 once every week.
Drug: Placebo
VRB-101 tablets will be administered orally.
Also known as: Oral Ecnoglutide
Placebo tablets will be administered orally.
Mean percent change from baseline in body weight
To evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in Schedule A dose regimens.
Time frame: From Baseline (Day 0) up to Week 21
Absolute change from baseline in body weight
To compare the effect of VRB-101 versus placebo on body weight in Schedule A.
Time frame: From Baseline (Day 0) up to Week 21
Percentage of participants who achieve 5% or more body weight reduction
To compare the effect of VRB-101 versus placebo on body weight in Schedule A
Time frame: From Baseline (Day 0) up to Week 21
Change from baseline in body mass index (BMI)
To compare the effect of VRB-101 versus placebo on body weight in Schedule A.
Time frame: From Baseline (Day 0) up to Week 21
Number of study participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
To assess safety and tolerability of study interventions. Adverse events (AEs) reported after first administration of study intervention will be designated as a TEAE.
Time frame: From Baseline (Day 0) up to Week 24
Change from baseline in blood pressure (BP)
To assess safety and tolerability of study interventions.
Time frame: From Baseline (Day 0) up to Week 24
Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS systematically assesses suicidal ideation and behavior using yes/no questions, ordinal severity ratings (0-5), and intensity subscales. Results at End of Study will be compared to Baseline.
Time frame: From Baseline (Day 0) up to Week 21
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Jul 2026, 7 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 7 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Verdiva Bio Dev Limited